

**(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. AU 2008257455 B2

(54) Title
Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis

(51) International Patent Classification(s)
A61K 35/74 (2006.01) C12Q 1/24 (2006.01)
A23C 9/12 (2006.01) C12R 1/225 (2006.01)
A23L 1/03 (2006.01) C12R 1/25 (2006.01)

(21) Application No: **2008257455** (22) Date of Filing: **2008.06.02**

(87) WIPO No: **WO08/145756**

(30) Priority Data

(31) Number **07380158.1** (32) Date **2007.05.31** (33) Country **EP**

(43) Publication Date: **2008.12.04**
(44) Accepted Journal Date: **2014.05.01**

(71) Applicant(s)
PULEVA BIOTECH, S.A.

(72) Inventor(s)
Sobrino Abuja, Odon Julian;Maldonado Barragan, Antonio;Arroyo Rodriguez, Rebeca;Xaus Pei, Jordi;Fernandez Alvarez, Leonides;Martin Jimenez, Rocio;Martin Merino, Virginia;Delgado Palacio, Susana;Sierra Avila, Saleta;Blanch Martell, Francesc;Olivares Martin, Monica;Jimenez Quintana, Esther Antonia;Marin Martinez, Maria Luisa;Torre Lloveras, Celina;Boza Puerta, Julio;Lara Villoslada, Federico;Jimenez Lopez, Jesus;Rodriguez Gomez, Juan Miguel

(74) Agent / Attorney
Collison & Co, Gpo Box 2556, Adelaide, SA, 5001

(56) Related Art
WO 2004/003235 A (PULEVA BIOTECH S A) 08 January 2004
WO 2005/117532 A (BIOGAIA AB) 15 December 2005
WO 2005/034970 A (TEAGASC ET. AL.) 21 April 2005

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 December 2008 (04.12.2008)

PCT

(10) International Publication Number
WO 2008/145756 A1

(51) International Patent Classification:

A61K 35/74 (2006.01) *A23L 1/03* (2006.01)
A23C 9/12 (2006.01) *C12R 1/225* (2006.01)
C12Q 1/24 (2006.01) *C12R 1/25* (2006.01)

[ES/ES]; Santa Isabel, 36, E-18110 Granada (ES). **FER-NÁNDEZ ÁLVAREZ, Leónides** [ES/ES]; Monasterio de Poyo, 24 - 2ºA, E-28049 Madrid (ES). **SOBRINO ABUJA, Odón Julián** [ES/ES]; Avda. Europa, 30 - portal 6 izqda, bajo C, E-28224 Pozuelo De Alarcón - Madrid (ES). **XAUS PEI, Jordi** [ES/ES]; Avda. Cervantes, 16 - Edif. Ciudad Real 7ºG Izqda., E-18008 Granada (ES). **RODRÍGUEZ GÓMEZ, Juan Miguel** [ES/ES]; Hierbabuena, 16 - 6, E-28770 Colmenar Viejo - Madrid (ES). **DELGADO PALACIO, Susana** [ES/ES]; Padre Suárez, 29; sótano, posterior dcha., E-33009 Oviedo - Asturias (ES).

(21) International Application Number:

PCT/EP2008/056768

(22) International Filing Date: 2 June 2008 (02.06.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
07380158.1 31 May 2007 (31.05.2007) EP

(74) Agent: **ARIAS SANZ, Juan**; ABG Patentes, S.L., Avenida de Burgos, 16D, Edificio Euromor, E-28036 Madrid (ES).

(71) Applicant (for all designated States except US): **PULEVA BIOTECH, S.A.** [ES/ES]; Camino de Purchil, 66, E-18004 Granada (ES).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(72) Inventors; and
(75) Inventors/Applicants (for US only): **MARTÍN JIMÉNEZ, Rocío** [ES/ES]; Gregorio Marañón, 8 - 7ºC, E-11202 Algeciras - Cádiz (ES). **OLIVARES MARTÍN, Mónica** [ES/ES]; Avda. Almendros, 162, E-18198 Huerto Vega - Granada (ES). **JIMÉNEZ QUINTANA, Esther Antonia** [ES/ES]; Travesía de la Cerca, 2, portal nº1 - 2ºC, E-28460 Los Molinos - Madrid (ES). **MARÍN MARTÍNEZ, María Luisa** [ES/ES]; Pasaje Hoyo de Manzanares, 6 - 1º izqda, E-28002 Madrid (ES). **SIERRA ÁVILA, Saleta** [ES/ES]; Pintor Zuloaga, 14 - 5ºB, E-18005 Granada (ES). **MALDONADO BARRAGÁN, Antonio** [ES/ES]; La Laguna, 45, E-41100 Coria Del Río - Sevilla (ES). **MARTÍN MERINO, Virginia** [ES/ES]; Peñascles, 2 - 1ºE, E-28028 Madrid (ES). **BLANCH MARTELL, Francesc** [ES/ES]; Canet, 37, baixos, 4º, E-08017 Barcelona (ES). **TORRE LLOVERAS, Celina** [ES/ES]; Ávila, 42, E-08195 Sant Cugat Del Vallés - Barcelona (ES). **LARA VILLOSLADA, Federico** [ES/ES]; Ciruelos, 18, E-18220 Albolote - Granada (ES). **ARROYO RODRÍGUEZ, Rebeca** [ES/ES]; Canillas, 4 - 2º 4, E-28850 Torrejón De Ardoz - Madrid (ES). **BOZA PUERTA, Julio** [ES/ES]; Sala Dos Hermanas, 81, E-18008 Granada (ES). **JIMÉNEZ LÓPEZ, Jesús**

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(54) Title: MAMMALIAN MILK MICROORGANISMS, COMPOSITIONS CONTAINING THEM AND THEIR USE FOR THE TREATMENT OF MASTITIS

(57) Abstract: The present invention relates to a novel approach to prevent or treat mastitis both in humans and animals through the use of mammal milk-derived microorganisms obtained from healthy hosts of the homologous species; to those new probiotic microorganisms obtained from milk able to reduce infectious mastitis and the method of screening used for their obtaining; to the use of these probiotic bacteria for the prophylaxis or treatment against mastitis and other diseases; and finally, to compositions comprising these compounds.

WO 2008/145756 A1

**MAMMALIAN MILK MICROORGANISMS, COMPOSITIONS CONTAINING
THEM AND THEIR USE FOR THE TREATMENT OF MASTITIS**

5 FIELD OF THE INVENTION

The present invention relates to a novel approach to prevent or treat mastitis both in humans and animals through the use of mammalian milk-derived microorganisms obtained from healthy hosts of the homologous species; to those new probiotic 10 microorganisms obtained from milk able to reduce infectious mastitis; to the use of these probiotic bacteria for the prophylaxis or treatment against mastitis and other diseases; and finally, to compositions comprising these compounds.

BACKGROUND OF THE INVENTION

15

Mastitis is an inflammation and infection of the mammary gland that is particularly frequent in women and other mammal females during lactation. Mastitis is mainly caused by staphylococci and/or streptococci selection and overgrowth in the mammary ducts and mammary areola glands. Human mastitis affects up to 30% of lactating 20 women and often leads to a precocious and undesired weaning because it is a really painful condition.

Moreover, mastitis is not human-specific pathology but affects to all mammalian species. In this sense, infectious mastitis in animal species and breeds reared for milk 25 production, such as cows, ewes or goats, is an important economic problem since milk produced during the infective process must be discarded due to the high bacterial and somatic cells counts. In addition, mastitis can be an important problem in those domestic species (pigs, rabbits...) and breeds (e.g., meat-producing bovine) not dedicated to milk production since a reduced milk supply of low bacteriological quality 30 may notably increase the morbidity and mortality rates among the offspring.

In these cases, antibiotic-based therapy has emerged as the unique therapeutical option. However, current wide-spectrum or Gram positive-targeted antibiotics are poorly

effective for the staphylococcal and streptococcal strains causing mastitis and, in fact, such treatments can be in some circumstances, detrimental because they usually eliminate the commensal flora that characterise mammal milk, which could exert some protective effects. Moreover, antibiotic therapy may result in the appearance of 5 antibiotic residues in the milk, which is also detrimental if occurring during the lactating period. Alternatively, recombinant bovine GM-CSF has also been used for the treatment of subclinical mastitis caused by *S.aureus* (Takahashi,H. et al. 2004, Cad.J.Vet.Res. 68:182-187) but did not prove efficient in the treatment of late-stage *S.aureus* infection.

10 An alternative approach for the treatment of mastitis is the use of probiotics. For instance, Sytnik,S.I. et al. (Vrach Delo., 1990, 3:98-100) attempted to use Bifidobacterium for preventing mastitis but did not observe any inhibition in the residence time of the breast microflora. Greene,W.A. et al. (J.Dairy Sci., 1991, 74:2976-2981) described the use of a commercial lactobacillus preparation for the treatment of 15 elevated somatic cell count (SSC) when administered by direct intramammary injection but conclude that the Lactobacillus product used in the assay was not effective as an intramammary treatment of subclinical mastitis based on SCC. The US patent US4591499 describes a method for treating mastitis using an intramammary injection of an oil in water emulsion containing a non-pathogenic lactobacillus strain or a mixture of 20 strains. However, the strains described in this document appear to act by means of a non-specific decrease in the pH in the mammary gland and, due to their particular formulation as emulsions, need to be administered by direct intramammary injection. The Russian patent RU2134583 describes the use of topic composition containing 25 lactobacterin (microbe mass of lactobacteria that have been live lyophilized/dried in culture medium) or bifidumbacterin (a lyophilised biopreparation immobilized on special activated charcoal) for the treatment of massive microbe dissemination of breast milk. However, this preparation is only suitable for the topic administration and forms part of a multi-step treatment that includes relaxation massage and application of a suspension of organisms derived from the normal microflora of the intestine 30 additionally containing a protective film-forming medium. The international patent application WO05/34970 describes the treatment of mastitis by direct intramammary injection of a *Lactococcus lactis* strain.

Therefore, all the prior art described above relate to the use of probiotic strains by either intramammary injection or topical application. Thus, there is a desire in the art for additional approaches to allow the prevention and treatment of mastitis and other mammary gland pathologies, in women and in other mammal females, which can be
5 more easily applied and by less invasive means.

SUMMARY OF THE INVENTION

The present invention is based on the unexpected and surprising finding that
10 mammalian milk contains probiotic strains that are able to be transferred to the mammary gland after their oral intake, and exert a therapeutic effect locally against the pathogens that cause mastitis, thus helping to reduce the incidence of mastitis. Moreover, these strains have a number of additional unexpected advantageous properties which make them useful for the treatment of other diseases. The present
15 invention is advantageous with respect to the methods known in the art in view of the valuable properties that lactation may provide, and due to the economic interest of milk productivity to farmers.

In a first aspect, the invention provides a process for the selection of probiotics
20 comprising the steps of:

- (i) isolating lactic acid bacteria or bifidobacteria strains present in the fresh milk from a mammalian species by selection in lactic acid culture media,
- (ii) selecting those strains from step (i) that are capable of being transferred to the mammary gland after oral intake and/or colonise the mammary gland
25 after its topical application,
- (iii) selecting those strains from step (ii) which are able to reduce the rates of survival and/or the rates of adhesion to epithelial cells of *Staphylococcus aureus* and
- (iv) selecting those strains from step (iii) that are capable of protecting animals
30 from mastitis.

In another aspect, the invention provides probiotic strains obtainable by the process of the invention.

In another aspect, the invention provides a supernatant of a culture of a strain or of a mixture of strains according to the invention.

In a further aspect, the invention provides a composition, a pharmaceutical product, a
5 feed or a nutritional product comprising at least a probiotic strain of the invention or a supernatant of a culture of one or more strains of the invention.

In another aspect, the invention provides the use of the probiotic strains of the invention or the culture supernatant for the manufacture of a medicament for the treatment and/or
10 prophylaxis of a chronic or acute infection or infestation, or of an undesirable microbial colonization, wherein the infection, infestation or colonization is caused by parasites, bacteria, yeast, fungi or viruses, affecting any body surface or mucosa in a subject or animal in need thereof.

15 In a further aspect, the invention provides the use of a probiotic strain or of a mixture of probiotic strains of the invention or the culture supernatant for the manufacture of a medicament for the treatment and/or prophylaxis of hypersensitivity reactions to food and metabolic intolerance; of constipation and other gastro-intestinal disorders; of inflammatory or auto-immune disorders selected from the group of IBD, ulcerative
20 colitis, arthritis, atherosclerosis, multiple sclerosis, psoriasis or sarcoidosis; and of tumour growth, metastasis and cancer in subject or animal in need thereof.

In a further aspect, the invention provides the use of a probiotic strain or of a mixture of probiotic strains or the culture supernatant of the invention for the manufacture of a
25 medicament for the treatment and/or prophylaxis of allergic disorders and asthma in a subject or animal in need thereof.

In a further aspect, the invention provides the use of a probiotic strain or of a mixture of probiotic strains or the culture supernatant of the invention for the manufacture of a
30 medicament for the treatment and/or prophylaxis of temporally depressed immune levels in individuals or animals subjected to physiological and management-derived stress.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 provides the sequences of the 16S rRNA sequences of the probiotic strains bacteria included in this invention and their PCR-RAPD profile.

5

Figure 2 is a graph bar showing the transfer ability to the mammary gland of and the gut colonization by the strains of the present invention in mice. The number of lactobacilli (grey bars), bifidobacteria (black bars) and enterococcus (white bars) in expressed milk and fecal samples in lactating mice supplemented daily for 14 days with 10^8 cfu of the 10 genetically-labeled strains was analyzed by bacterial colony plating. Milk and fecal samples were collected at day 0, 5 and 10 of probiotic supplementation. PCR-positive colonies in milk are indicated as %.

Figure 3 is a graph bar showing the inhibition of the staphylococcal survival and 15 adhesion produced after co-culture of the staphylococci with the strains included in this invention. A) The inhibitory effect of the probiotics included in this invention on *Staphylococcus aureus* survival was assessed *in vitro* by an agar well diffusion assay in TSA plates. The diameter of the inhibition halo (in millimetres) caused by the bacterial supernatants determines the antimicrobial effect. B) The adhesion of the pathogenic 20 *Staphylococcus aureus* strain to Caco-2 cells was assessed in the presence of the probiotic strains of this invention. Ten randomized fields were counted and the results expressed as the mean of the % of adhered gram-negative bacteria attached to the cells compared to the number of pathogenic bacteria adhered in absence of probiotics.

25 Figure 4 is a graph bar showing the protection from staphylococcal mastitis. Mastitis was induced in lactating mice 10 days post-parturition by injection of 10^6 cfu of *S. aureus* in the fourth mammary pair. Staphylococcal load in the expressed milk (A) and the inflammatory mammary score (B) was evaluated after 5 and 10 days of infection.

30 Figure 5 is a graph bar showing the adhesion of probiotic strains to intestinal cells. The adhesion of the probiotic strains of this invention was assessed using Caco-2 (grey bars) or HT-29 (black bars) intestinal cell lines. Twenty randomized fields were counted and

the results expressed as the mean of the number of bacteria attached to the cells per field \pm SD.

Figure 6 is a graph bar showing the survival of probiotic strains to digestion-resembling conditions. The resistance of the probiotic strains of this invention to acidic (grey bars) and high bile salt content (black bars) was assessed *in vitro* by culture of the bacteria in MRS pH 3.0 or 0.15% bile salts for 90 minutes. The results are represented as the mean \pm SD of three independent experiments.

Figure 7 shows the effect of the probiotic strains on a model of orally-induced *Salmonella* infection. A) Graph bar showing the effect of probiotic treatment in the inhibition of *Salmonella* translocation to the spleen. The number of *Salmonella* colonies was measured in the spleens of mice treated with the probiotics, with (grey bars) or without vaccination (black bars) with 10^8 cfu of inactivated *Salmonella*, after 24 hour of an oral challenge with 10^{10} cfu *Salmonella*. B) Survival curves of the animals after *Salmonella* infection.

Figure 8 is a graph bar showing the effect of probiotic strains on cytokine and immunoglobulin G expression. The TNF- α (A) and IL-10 (B) cytokine production was analyzed in bone marrow-derived macrophages stimulated with LPS and the indicated probiotic strain for 12 hours while IgG expression (C) was analyzed in lymphocytes obtained from the spleen of Balb/c mice (6-8 weeks old) stimulated with LPS and the indicated probiotic strain for 6 days. Both cytokine and IgG production were detected by ELISA.

25

DETAILED DESCRIPTION OF THE INVENTION

The invention provides a new method for the prophylactic and therapeutic treatment of infectious mastitis both in women and other mammal females in need thereof. The method is based in the use of specific probiotic strains specially selected for that particular application.

In a first aspect, the invention provides a process for the selection of probiotics comprising the steps of:

- (i) isolating lactic acid bacteria or bifidobacteria strains present in the fresh milk from a mammalian species by selection in lactic acid culture media,
- 5 (ii) selecting those strains from step (i) that are capable of being transferred to the mammary gland after oral intake and/or colonise the mammary gland after its topical application,
- (iii) selecting those strains from step (ii) which are able to reduce the rates of survival and/or the rates of adhesion to epithelial cells of *Staphylococcus aureus* and
- 10 (iv) selecting those strains from step (iii) that are capable of protecting animals from mastitis.

In step (i), any milk obtained from a mammalian organism can be used as starting material for the process of the invention. In a preferred embodiment, the milk used is human, bovine, porcine, sheep, cat or canine milk. Moreover, any lactic acid culture media known in the art can be used for selecting the strains. Preferably, the lactic acid culture media is selected from MRS medium, APT medium, RCM medium, LM17 medium, GM17 medium and Elliker medium. Most preferably, the lactic acid culture media is MRS medium.

In step (ii), the strains isolated in step (i) are selected based on their ability to be transferred to the mammary gland after oral intake and/or colonise the mammary gland after topical application. For detecting the ability to be transferred to the mammary gland, an assay such as described in WO2004003235 for detecting transfer of a microorganism to the milk after oral intake can be used.

In step (iii), any assay known in the art for measuring survival rates of *Staphylococcus aureus* and for measuring adhesion rates of *S. aureus* to epithelial cells can be used. In a preferred embodiment, the effect of the probiotics on the adhesion rates is measured using a confluent culture of an intestinal cell line to which the *S. aureus* cells and the probiotics of the invention are added and the number of attached *S. aureus* cells is measured by any suitable technique. Typically, the intestinal cell line is Caco-2 and the

number of attached cells is measured by direct inspection of the cell monolayers under light microscopy. Moreover, the selection step (iii) may also or alternatively involve measuring the viability of *S.aureus* in the presence of the probiotic strains. Any assay suitable for measuring growth inhibition of bacterial strains may be used.

5 Typically, the assessment of *S.aureus* viability is carried out by an agar well diffusion assay.

In step (iv), any assay to measure protection of mastitis can be used. Preferably, the assay involves using an animal model of mastitis wherein at least one of the pathogens 10 known to be the causative agent of mastitis is injected into the mammary gland. More preferably, the animal model is a mouse and the pathogen that needs to be administered to cause mastitis is *S.aureus*.

In another aspect, the invention provides a probiotic strain which is obtainable by the 15 process of the invention. Preferably, the probiotic strain is selected from the group of *Bifidobacterium breve* deposited in the CECT under Accession Nº 7263, *Bifidobacterium breve* deposited in the CECT under Accession Nº 7264, *Lactobacillus reuteri* deposited in the CECT under Accession Nº 7260, *Lactobacillus plantarum* deposited in the CECT under Accession Nº 7262, *Lactobacillus fermentum* in the CECT 20 under Accession Nº 7265, *Lactobacillus reuteri* deposited in the CECT under Accession Nº 7266, *Lactobacillus salivarius* deposited in the CECT under Accession number 7409, *Enterococcus hirae* deposited in the CECT under Accession number 7410, *Enterococcus faecalis* deposited in the CECT under Accession number 7411, *Lactobacillus plantarum* deposited in the CECT under Accession number 7412, 25 *Lactobacillus reuteri* deposited in the CECT under Accession number 7413.

In a further aspect, the invention provides a supernatant of a culture of one or more of the strains according to the invention. The supernatant can be obtained from the culture by any means available to the skilled person, including centrifugation, filtration, 30 flotation and the like.

In a further aspect, the invention provides a probiotic strain or a mixture of probiotic strains according of the invention or a supernatant of a culture of one or more of the strains according to the invention for use as a medicament..

- 5 In another aspect, the invention provides a composition which comprises at least one of the bacterial strains of the invention. Preferably, the composition comprises at least 2, at least 3, at least 4, at least 5 or at least 6 of the strains of the invention, and wherein each of the strains is represented in the composition in a proportion from 0.1% to 99.9%, preferably from 1% to 99%, more preferably from 10% to 90%. In another embodiment,
- 10 the composition comprises any of the bacterial strains of the invention together with another strain or mixture of strains and where each of the strains is represented in the composition in a proportion from 0.1% to 99.9%, preferably from 1% to 99%, more preferably from 10% to 90%. In another aspect, the invention provides a composition which comprises a supernatant of a culture of one or more of the strains according to the
- 15 invention. Preferably, the supernatant is represented in the composition in a proportion from 0.1% to 99.9%, more preferably from 1% to 99% and even more preferably from 10% to 90%.

In another aspect, the invention provides a pharmaceutical composition comprising a therapeutically effective amount of at least one strain or a composition of the invention or of a supernatant of a culture of one or more of the strains according to the invention. The pharmaceutical preparation can take the form of tablets, capsules, liquid bacterial suspensions, dried oral supplements, wet oral supplements, dry tube feeding or a wet tube feeding. Preferably the probiotic, the probiotic-containing or supernatant-containing composition and pharmaceutical product is directed to the oral, gastric and/or to the intestinal mucosal surface; however, it could also be directed to nasopharingeal, respiratory, reproductive or glandular mucosa, and/or to the mammary gland and it could be administered to women and animals by an oral, nasal, ocular, rectal, topical and/or vaginal route.

30

In another aspect, the invention provides a feed or a nutritional product comprising at least a probiotic strain according to the invention or of a supernatant of a culture of one or more of the strains according to the invention. Non-limiting examples of suitable

foodstuffs which can be used in the present invention are milk, yoghurt, cheese, curd, fermented milks, milk based fermented products, fermented cereal based products, fermented meat products, other milk based or cereal based powders, clinical nutrition formula, ice-creams, juices, bread, cakes or candies, animal feed formulations, semi- or 5 synthetic diet formulations, infant formulae, clinical nutrition formulae, ice-creams, juices, flours, bread, cakes, candies or chewing-gums.

The required dosage amount of the probiotic strains in the composition, food or pharmaceutical composition described before will vary according to the nature of the 10 disorder or the proposed use of the composition, whether used prophylactically or therapeutically and the type of organism involved.

Any suitable dosage of the probiotics or combinations thereof may be used in the present invention provided that the toxic effects do not exceed the therapeutic effects. 15 Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures with experimental animals, such as by calculating the ED, (the dose therapeutically effective in 50% of the population) or LD (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD/ED ratio. Nevertheless, the activity of the new 20 microorganisms in the individual is naturally dose dependent. That is, the more the novel microorganisms are incorporated by means of ingesting or administration of the above food material or the pharmaceutical composition, the higher protective and/or therapeutic activity of the microorganisms. Since the microorganisms of this invention are not detrimental to mankind and animals and have eventually been isolated from 25 healthy human breast milk, a high amount thereof may be incorporated so that essentially a high proportion of the individual's mucosa will be colonized by the novel microorganisms. Compositions which exhibit large therapeutic indices are preferred. The data obtained from animal studies are used to formulate a range of dosage for human or animal use. The dosage contained in such compositions is preferably within a 30 range of circulating concentrations that includes the ED, with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration. The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring

treatment. For instance, for preparing a food composition according to the present invention at least one of the probiotic strains of the present invention is incorporated in a suitable support, in an amount of from 10^5 cfu/g to about 10^{12} cfu/g support material, preferably from about 10^6 cfu/g to about 10^{11} cfu/g support material, more preferably 5 from about 10^6 cfu/g to about 10^{10} cfu/g support material.

In the case of a pharmaceutical composition, the dosage of the probiotic strain should be from about 10^5 cfu/g to about 10^{14} cfu/g support material, preferably from about 10^6 cfu/g to about 10^{13} cfu/g support material, more preferably from about 10^7 cfu/g to 10 about 10^{12} cfu/g support material. For the purpose of the present invention the abbreviation cfu shall designate a "colony forming unit" that is defined as the number of bacterial cells as revealed by microbiological counts on agar plates.

Dosage and administration are adjusted to provide sufficient levels of the active moiety 15 or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and 20 clearance rate of the particular formulation.

In a preferred embodiment, the invention also refers to compositions of the strains of this invention in a lyophilized, freeze dried or dried form, which can be obtained by any conventional method known in the art.

25 In another aspect, the invention provides a composition, pharmaceutical product, feed or nutritional product wherein the probiotic strain or the mixture thereof is in a partially or totally inactivated form.

30 Many people have a disturbed intestinal microflora, that is, the balance between useful and harmful intestinal bacteria is disturbed. A number of factors, among others stress, the presence of bile salts, and specially diet, influence the bacterial flora. In these situations the fermentation process could be disturbed and the number of useful bacteria

be reduced, with the consequence that the colon mucosa withers away and ceases to function at the same time as the potentially malignant bacteria rapidly grow in number. The probiotic strains of the invention are capable of preventing adhesion of *S.aureus* to epithelial cells, as well as of reducing survival rates of *S.aureus* cells and of many other 5 pathogens. Thus, the probiotic strains of the invention are particularly useful for the treatment of said diseases since they contribute effectively to the killing of the pathogens while at the same time; they contribute to the repopulation of the mucosal surface with the physiological microflora.

10 For this reason, one aspect of this invention is the use of probiotics of the invention and of the supernatants of a culture of one or more strains of the invention for the preparation of a pharmaceutical composition for the prophylactic or therapeutic treatment of chronic or acute infection, or infestation or of undesirable microbial colonization, of a mucosal surface or any other human location, wherein the infection, 15 infestation or colonization is caused by parasites, bacteria, yeast, fungi or viruses, affecting any body surface or mucosa, said therapeutic treatment comprising the administration of an effective amount of a probiotic, or a probiotic-containing composition, to a subject in need thereof. In a preferred embodiment, the infection or colonization is caused by parasites, bacteria, yeast, fungi or viruses, of any body surface 20 or mucosa in a subject or animal in need thereof.

The probiotics of the invention have been selected based on their ability to colonise the mammary gland after oral intake and to prevent adhesion to epithelial cells and to decrease survival of *S.aureus*. Thus, the strains are suitable for treatment of mastitis. 25 Accordingly, in a further aspect, the invention provides the use of the probiotic strains of the inventions and of the supernatants of a culture of one or more strains of the invention for the preparation of a pharmaceutical composition for the treatment or prophylaxis of human and animal infectious mastitis. This process consists in the use of probiotic strains selected from homologous fresh milk and in the ability of these strains 30 to be transferred to the mammary gland and exert there their benefits, such as the inhibition of the staphylococcal infection.

Moreover, the probiotic strains of the invention have also been shown to possess some of the characteristics attributed to a potential probiotic strain, namely safety and good resistance to digestion process and the ability of gut colonization. Therefore, the strains are capable of reaching the intestinal tract after oral intake and exert their therapeutic properties there. Accordingly, in a preferred embodiment, the invention provides the use of the probiotic strains of the invention and of the supernatant of a culture of one or more of the strains of the invention for the preparation of a pharmaceutical composition for the treatment of neonatal diarrhoea.

10 The probiotic strains are known to reduce the production of pro-inflammatory cytokines by activated macrophages during chronic inflammatory disorders. Accordingly, in another aspect, the invention provides the use of the bacterial strains, compositions of the invention and supernatants of a culture of one or more strains of the invention for the preparation of a pharmaceutical composition for the manufacture of a medicament for the treatment of inflammatory or auto-immune disorders. Non-limiting examples of such inflammatory and autoimmune diseases include IBD, ulcerative colitis, arthritis, atherosclerosis, multiple sclerosis, psoriasis or sarcoidosis.

20 The probiotic strains according to the invention are capable of repopulating the immune gut barrier after oral intake and thus, they are also particularly suitable for the improvement of the immune gut barrier in a subject or animal in need thereof. Accordingly, in another aspect, the invention provides the use of one or more probiotic strains of the invention and of the supernatants of a culture of one or more strains of the invention for the preparation of a pharmaceutical composition for the preparation of a medicament for the treatment and/or prophylaxis of hypersensitivity reactions to food and metabolic intolerance such as lactose intolerance; of constipation and other gastrointestinal disorders.

30 Probiotics are known to be useful for counteracting cancer due to their effects in the inhibition of carcinogenic toxins in the intestines such as nitrosamines but also for the effect of this probiotics in the modulation of the natural immune response. Accordingly, in a further aspect, the invention provides the use of the strains stated in this invention and of the supernatants of a culture of one or more strains of the invention for the

preparation of a pharmaceutical composition for the prophylactic or therapeutic treatment of some cancer types and for inhibiting tumor growth, metastasis and cancer in subject or animal in need thereof.

5 The strains of the invention are capable of modulating the immune response and the balance between Th1 and Th2 cytokines. Accordingly, in a further aspect, the invention provides the use of the strain, compositions and supernatants of the invention in the manufacture of a medicament for the treatment and/or prophylaxis of allergic disorders, asthma and disorders related with the development of tolerance against ingested 10 proteins.

In a further aspect, the invention provides the use of the strains, compositions and supernatant of the invention in the manufacture of a medicament for the treatment and/or prophylaxis of temporally depressed immune levels in individuals such as 15 produced during aging or in healthy individuals who are subject to intense exertion or in general to a great physiological strain or stress.

In another aspect, the invention provides for the therapeutic use of the probiotic strain, of the combinations of strains and of the supernatants wherein the strain or strains are 20 administered via oral, topic, nasal, enteral, ocular, urogenital, rectal or vaginal.

Moreover, due to the presence of the selected strains in breast milk, the subjects in need of treatment could be not only those who intake directly the selected strains but also the fetus or breast feeding babies. Accordingly, in still a further aspect, the invention 25 provides the use of the strains, compositions and supernatant of the invention in the manufacture of a medicament designed to be administered to lactating woman for the therapeutic or prophylactic treatment of their fetus and/or their breastfed babies.

The following methods and examples illustrate the invention.

30

EXAMPLES

Example 1: Isolation of probiotics from mammal milk

Fresh milk samples (2 ml except in the case of the bitches where only 0.5 ml were collected) were obtained from 23 healthy women at day 6-14 after labour; 8 sows at day

5 5 after labour, 9 bitches at day 2-10 after labour and 4 cows at day 2 after labour.

Neither the women nor the animals had complications during labour and no antibiotic therapy was administered in the last two weeks prior milk sample collection. All milk samples were immediately frozen at -80°C.

10 In order to isolate bacterial strains from these samples, serial dilutions of 0.1 ml in peptone water were plated on MRS, APT, RCM, LM17, GM17 and Elliker agar plates at 37°C in both aerobic and anaerobic conditions for 24-48 hours. Among the approx. 1200 colonies initially obtained, 120 (10%; include representatives of the different morphologies observed on the plates) were selected and subcultured in MRS agar at 15 37°C in anaerobic conditions. Among them, we further selected 68 isolates with the following characteristics: non-spore-forming, catalase- and oxidase-negative Gram positive rods.

These 68 selected isolates were further characterized both phenotypically (API CH50,

20 APIZYM and antibiotic resistance evaluation) and genetically (16S rRNA sequencing and RAPD-PCR profile). This characterization resulted in 59 different bacterial strains which were further evaluated through the screening process described in this invention in order to obtain potential probiotic candidates to be able to protect against mastitis.

25 After this screening process, only 6 strains (2 from women, 2 from bitches and 2 from sows) fulfilled all the defined criteria. Other lactic acid bacteria strains were obtained from other mammal species, such as goat, ewe, cat, rat and mice, but they were not successful to fulfil all the screening criteria and for this reason they are not included in this invention.

30

- *Bifidobacterium breve* said bacteria being obtained from human milk
- *Bifidobacterium breve* said bacteria being obtained from human milk
- *Lactobacillus reuteri* said bacteria being obtained from porcine milk

- *Lactobacillus plantarum* said bacteria being obtained from porcine milk
- *Lactobacillus reuteri* said bacteria being obtained from canine milk
- *Lactobacillus fermentum* said bacteria being obtained from canine milk
- *Lactobacillus salivarius* said bacteria being obtained from porcine milk
- 5 • *Enterococcus hirae* said bacteria being obtained from feline milk
- *Enterococcus faecalis* said bacteria being obtained from feline milk
- *Lactobacillus plantarum* said bacteria being obtained from feline milk
- *Lactobacillus reuteri* said bacteria being obtained from canine milk

10

Example 2: Physiologic and genetic characterization

All these isolates were physiological and genetically characterized. For the identification of each probiotic strain, we performed a fermentation API 50CH 15 (BioMerieux) analysis of the strains at 37°C in anaerobic conditions for 24 and 48 hours, following the manufacturer instructions. The 24 hours results were summarized in Table I. A positive fermentable substrate is that with a value higher than 3.

Due to the low specificity of the API characterization, we also performed the analysis of 20 the 16S rRNA sequences of the selected bacterial strains. The 16S RNA sequence of the selected bacteria and their RAPD-PCR profile are shown in Figure 1. The results obtained led to the classification of the bacterial strains as indicated above. With this classification the bacterial strains of the invention were deposited according to the Budapest Agreement at the CECT -*Colección Española de Cultivos Tipo-*, Valencia 25 (Spain) on April 17th 2007 and accorded the following accession numbers:

- *Bifidobacterium breve* CECT7263
- *Bifidobacterium breve* CECT7264
- *Lactobacillus reuteri* CECT7260
- 30 • *Lactobacillus plantarum* CECT7262
- *Lactobacillus reuteri* CECT7265
- *Lactobacillus fermentum* CECT7266

The following bacterial strains of the invention were deposited according to the Budapest Agreement at the CECT -*Colección Española de Cultivos Tipo-*, Valencia (Spain) on May 30th, 2008

5 • *Lactobacillus salivarius* CECT 7409
 • *Enterococcus hirae* CECT 7410
 • *Enterococcus faecalis* CECT 7411
 • *Lactobacillus plantarum* CECT 7412
 • *Lactobacillus reuteri* CECT 7413

10

Table 1: Fermentation pattern of the different probiotic strains of the invention Positive fermentable substrates are indicated in grey.

TEST	7263	7264	7260	7262	7265	7266	7413	7412	7409	7411	7410
Glycerol	0	0	0	0	0	0	0	0	0	0	0
Erythritol	0	0	0	0	0	0	1	0	0	0	0
D-Arabinose	0	0	0	0	0	0	5	0	0	5	5
L-Arabinose	0	0	0	5	0	5	5	5	0	1	0
Ribose	5	0	0	5	5	5	5	5	4	0	0
D-Xylose	0	0	0	0	0	5	0	0	0	0	0
L-Xylose	0	0	0	0	0	0	0	0	0	5	5
Adonitol	0	0	0	0	0	0	5	0	0	5	5
β -Methyl-D-xyloside	0	0	0	0	0	5	5	0	0	5	5
Galactose	5	6	5	5	5	5	5	5	5	5	5
D-Glucose	5	5	5	5	5	5	0	5	5	0	0
D-Fructose	5	5	0	5	6	0	5	5	5	0	0
D-Mannose	1	0	0	5	5	0	0	5	5	0	0
L-Sorbose	0	0	0	0	0	0	0	0	0	5	0
Rhamnose	0	0	0	0	0	0	0	0	0	5	0
Dulcitol	0	0	0	0	0	0	0	0	0	0	0
Inositol	0	0	0	0	0	0	0	0	0	0	0
Mannitol	4	0	0	5	5	0	4	5	5	5	5
Sorbitol	5	0	0	5	0	0	0	5	5	5	5
β -Methyl-D-mannoside	0	0	0	0	0	0	0	0	0	0	5
β -Methyl-D-glucoside	2	0	0	0	5	0	5	0	0	5	5
N-Acetyl glucosamine	2	1	0	5	5	0	5	5	5	5	5
Amygdaline	0	1	0	5	0	0	5	5	0	5	5
Arbutine	0	0	0	5	0	0	5	5	4	5	5
Esculetine	5	5	0	5	0	0	0	5	5	5	5
Salicin	1	0	0	5	0	0	5	5	0	0	5
Celllobiose	5	0	0	5	0	0	5	5	4	5	5
Maltose	5	5	5	5	5	5	5	5	5	5	5
Lactose	5	0	5	5	5	5	5	5	5	0	0
Maltobiose	5	6	6	5	5	5	5	5	5	5	0
Saccharose	5	0	5	0	5	5	5	0	5	0	0
Trehalose	0	0	0	5	0	0	0	5	5	1	5
Inuline	0	0	0	0	0	0	0	0	0	0	0
Melizitose	0	0	0	0	0	0	5	0	0	0	0
D-Raffinose	5	0	5	5	5	5	0	5	5	0	0
Amidon	5	0	0	0	0	0	0	0	0	0	0
Glycogen	5	4	0	0	0	0	0	0	0	5	0
Xylitol	0	0	0	0	0	0	5	0	0	0	0
β -Gentobiose	0	2	0	5	0	0	0	5	0	0	0
D-Turanose	5	4	0	5	0	0	0	5	0	0	0
D-Lyxose	0	0	0	0	0	0	5	0	0	0	0
D-Trehalose	0	0	0	0	0	0	0	0	0	5	0
D-Fucose	0	0	0	0	0	0	0	0	0	1	0
L-Fucose	0	0	0	0	0	0	0	0	0	0	0
D-Arabinol	0	0	0	0	0	0	0	0	0	0	0
L-Arabinol	0	0	0	0	0	0	0	0	0	0	0
Gluconate	0	0	0	0	0	0	0	0	0	0	0
2 ceto-gluconate	0	0	0	0	0	0	0	0	0	0	0
5 ceto-gluconate	0	0	0	0	0	0	0	0	0	0	0

15 **Example 3: Selective screening of the strains**

Example 3a: Transfer to the mammary gland after oral intake

Once the different candidate strains were obtained from mammal milk as indicated in the first selection criteria, the following step in the selection process described in the present invention is that bacteria should be able to be transferred to milk after oral intake or topic application. In order to test this capability, the putative strains were 5 genetically labelled as described previously (WO 2004/003235) and orally administered to pregnant rats as animal model. Total lactobacilli, bifidobacteria and enterococcus were measured in milk and neonatal fecal samples. Moreover, specific transfer of bacteria was analyzed by PCR screening of the colonies obtained from the milk of lactating rats and from the neonatal faeces.

10

Four pregnant Wistar rats were orally inoculated with 10^8 cfu of genetically-labelled strains vehiculated in 0.5 ml of milk every two days from two weeks before labor. After labor, the transfer of genetically labelled bacteria to breast milk was analyzed by comparison of the bacteria isolated from the neonatal faeces at day 0, 5 and 10 after 15 labor. All the plates were incubated for 24 hours at 37°C under anaerobic conditions. For each sample obtained, total bifidobacteria, lactobacilli and enterococcus counts were measured. Among the colonies that grew on MRS plates, 50 were randomly selected from each sample and subcultured on Cm-MRS plates. Finally, the Cm-resistant colonies were used as templates to detect the specific genetic label colonies 20 (Figure 2). Transfer was considered positive when at least 1% of the colonies obtained were PCR-positive.

Example 3b: Inhibition of *Staphylococcus aureus* survival

25 The probiotic strains of this invention were assessed for their capability to produce bactericidal metabolites able to reduce the survival of *Staphylococcus aureus* using an agar well diffusion assay. TSA agar plates containing 10^6 cfu/ml of *S. aureus* were prepared. Wells with a diameter of 5 mm were cut in the agar using a sterile cork-borer. Then, 50 µl of a 2-fold concentrated supernatant of each probiotic strain solution 30 were added to the wells and allowed to diffuse into the agar during a 2 hours preincubation period at 4°C, followed by aerobic incubation of the plates at 37°C for 16-18 hours. After the incubation period, an inhibitory halo was observed and measured (in millimetres) to evaluate the bactericide effect of the probiotic candidates (Figure 3A).

Example 3c: Inhibition of *Staphylococcus aureus* adhesion to epithelial cells

Caco-2 intestinal cell lines were cultured to confluence in 35 mm plastic dishes containing 2 ml medium without antibiotics. On day 10-14 post-confluence, 1 ml of media was replaced with 1 ml of a suspension of 10^8 probiotic bacteria in DMEM. The cultures were incubated 1 hour at 37°C. After that, 1 ml of a suspension of 10^8 pathogenic bacteria (*S. aureus*) in DMEM was added to the cultures and incubated 1 hour more at 37°C. The cells were washed twice with PBS and fixed with ice-cold 70% methanol for 30 minutes. Plates were air dried and Gram stained. The attached bacteria were visualized using an optical Axiovert 200 (Zeiss) microscope at 1000x magnification in oil-immersion. The number of gram-negative bacteria in 10 randomized fields was counted and the results expressed as the mean of % of pathogenic bacteria attached to the cells compared to control cultures without probiotic strains (Figure 3B).

15

Example 3d: Protection of mastitis

To evaluate the efficacy of the probiotic candidates to protect against mastitis, we used a mice model of this pathology. In brief, 10 Wistar pregnant rats per group were daily supplemented by oral gavage with 10^8 cfu/day of each probiotic strain vehiculated in 200 µl of milk during two weeks after labour. One week after labour, mastitis infection was induced in the animals by injection of 10^6 cfu of *S. aureus* in the fourth mammary gland pair. Expressed milk was collected at days 0, 5 and 10 post-infection to measure bacterial load (Figure 4A); and 5 animals of each group were sacrificed at days 5 and 10 post infection in order to obtain mammary gland biopsies to evaluate the inflammatory process by histological examination.

Whole glands were fixed in 5% formalin and dehydrated with alcohol, and finally embeded in paraffin. Tissue sections were stained with haematoxylin-eosin and examined in a blinded fashion (Figure 4B). To qualitatively evaluate alterations of mammary gland histology, an inflammatory index value (IIV) was determined as follow:

- Score 0: No infiltration

20

- Score 1: Mild PMN cell interstitial infiltration in isolated areas of tissue sections, undamaged tubular epithelium
- Score 2: Interstitial infiltration covering most fields, dispersed areas of tissue damage with loss of tissue structure, and scant images of abscess formation
- Score 3: Severe infiltration covering most fields, frequent areas of tissue damage with loss of tissue architecture, and frequent images of abscess formation.

10 **Example 4: Probiotic potential of the strains**

The selected strains were further analyzed for different characteristics that could enhance their capabilities to act as a probiotic strains. The results obtained are described in the indicated examples.

15

Example 4a: Adhesion to Caco-2 and HT-29 cells

For the adhesion assays the cell lines Caco-2 (ATCC HTB-37) and HT-29 (ATCC HTB-38) were utilized as a model of the intestine cells. Both cell lines presented 20 features characteristic for intestinal cells such as polarization, expression of intestinal enzymes, production of particular structural polypeptides and mucins.

The cells were grown in plastic flasks (75 cm², Nunc) in DMEM as culture medium supplemented with 10% inactivated FCS, non essential amino acids, 100 U/ml 25 penicillin/streptomycin, 1 µg/ml amphotericine. Culturing was performed at 37°C in an atmosphere comprising 95% air and 5% CO₂. Media was changed on a two daily basis and the cells were split every week.

Caco-2 and HT-29 intestinal cell lines were split in 35 mm plastic dishes in 2 ml 30 medium without antibiotics to confluence. 10-14 days post-confluence, 1 ml of media was replaced with 1 ml of a suspension of 10⁸ bacteria in DMEM (PAA). The cultures were incubated 1 hour at 37°C. After that, cells were washed twice with PBS and fixed with ice-cold 70% methanol for 30 minutes. Plates were air dried and Gram stained.

The attached bacteria were visualized using an optical Axiovert 200 (Zeiss) microscope at 1000x magnification in oil-immersion. Twenty randomized fields were counted and the results expressed as the mean of the number of bacteria attached to the cells per field \pm SD (Figure 5)

5

Example 4b: Resistance to acid and bile salts

To analyze the resistance of the probiotic strains of this invention to acidic and high bile salt content, conditions that these bacteria will encounter during the digestive transit, 10 bacteria were cultured in MRS broth medium pH 3.0 or with 2 % bile salts (Sigma) for 90 minutes. The survival was calculated by MRS agar plating of serial dilutions and compared to the number of colonies obtained in control conditions (MRS broth pH 5.8). Plates were cultured 24 hours at 36°C in extreme anaerobic conditions. The experiment was repeated three times (Figure 6).

15

Example 4c: Resistance to antibiotics

The use of modern antibiotics leads to a reduction of the comensal gut microflora which sometimes relates to diarrhoea and other gut disorders. Moreover, this reduction in the 20 amount of gut bacteria could be the consequence of opportunistic pathogenic bacteria and viruses to infect the host. The use of antibiotics to block the infection does not resolve this disorder but complicates it. In other situations like intestinal inflammation where probiotics could exert a beneficial role, this potential effect is sometimes limited for the simultaneous therapy with antibiotics. For all these reasons, the selection of 25 potential probiotic strains which were able to resist common antibiotics should be clearly interesting.

To analyze the resistance of the probiotic strains of this invention we used a agar well diffusion assay. Müller-Hinton agar plates containing 10^6 cfu/ml of each probiotic 30 strain were prepared. Then, antibiotic commercial discs were added to the wells and allowed to diffuse into the agar during 10 minutes preincubation period at room temperature, followed by extreme anaerobic incubation of the plates at 36°C for 16-18 hours.

The antibiotic resistance of the probiotic strains of this invention is summarized in Table II.

5

Table II: Antibiotic resistance of the different probiotic strains of the invention

	7263	7264	7260	7262	7265	7266	7413	7412	7409	7411	7410
Penicillin	S	S	R	S	S	R	R	S	S	S	S
Ampicillin	S	S	R	S	S	R	R	S	S	S	S
Ciprofloxacin	S	S	S	S	R	S	S	S	S	S	S
Erythromycin	S	S	S	S	S	S	S	S	S	S	S
Clindamycin	S	S	S	S	S	S	S	S	S	R	R
Tetracycline	S	S	S	S	S	S	S	S	S	S	R
Vancomycin	S	S	R	R	R	R	R	R	R	S	S
Gentamicin	R	R	S	S	R	S	S	S	S	S	S
Cloramphenicol	S	S	S	S	S	S	S	S	S	S	S
Rifampicin	S	S	S	S	S	S	S	S	S	S	R

Example 4d: Production of antimicrobial metabolites

10

It has been suggested that the main mechanism used by probiotics is controlling the balance between useful and harmful intestinal bacteria is the gut. When the number of useful bacteria is reduced, opportunistic bacteria could over-grow and disturb the well-being of the host or even induce an infection. Most bacterial organisms have acquired

15 characteristics or mechanisms that reduce the growth capabilities of other microorganisms that cohabit with them and thus, enabling their selective growth. The reduction of pH through acid production by lactic acid bacteria is one of such mechanisms. Moreover, some lactic acid bacteria also produce bioactive peptides components and other metabolites that selective inhibit the growth of other bacteria, 20 yeast or fungi. This is the case of reuterin (an aldehyde) or bacteriocins (peptides, such as nisin or pediocin PA-1).

The probiotic strains of this invention were assessed for their capability to produce bactericidal metabolites using an agar well diffusion assay. TSA agar plates containing 25 10^6 cfu/ml of different pathogenic bacteria strain were prepared and assayed as previously indicated in Example 3b for *S. aureus*. Results obtained were described in Table III.

Table III: pathogen inhibitory potential of the different probiotic strains of the invention

	7413	7412	7409	7411	7410	7263	7264	7260	7262	7265	7266
<i>E. faecium</i> P21	+	+	+	-	-	+++	+++	+	+	+++	+++
<i>E. faecalis</i> TAB28	+++	+++	+++	-	-	++	+++	+++	+++	+++	+-
<i>L. monocytogenes</i> Scott A	++	+-	+	+-	+-	+++	++	++	+-	+	+++
<i>L. innocua</i> RdC	+	+-	+	+-	+-	++	++	+-	+	+-	+-
<i>E. coli</i> CECT 4076	+++	+++	+++	+	+	+++	+	+++	+++	+++	+++
<i>E. coli</i> RIM1	+++	+++	+++	+	+	+	+++	++	+++	+++	+-
<i>S. enteritidis</i> 4396	+++	+++	+++	++	++	+-	++	++	+++	++	++
<i>K. pneumoniae</i> CECT142	++	+++	+++	++	+++	+++	+	++	+	+++	++
<i>K. oxytoca</i> CECT860T	+-	+	+++	++	++	+++	+++	+-	+-	+-	++
<i>P. vulgaris</i> CECT484	++	++	++	+	+	+-	+	+++	+++	++	+-
<i>S. aureus</i> CECT5191	+++	++	++	++	++	+++	++	+++	++	+++	+++
<i>S. epidermidis</i> CECT231	++	++	+++	++	++	++	+++	+++	++	++	++

Example 5: Effect of the probiotic strains of this invention on translocation of *Salmonella typhimurium* in mice following immunization with inactivated *Salmonella* vaccine

Translocation of gram-negative bacteria across the gut epithelium can occur especially in subjects following gastrointestinal infection, disease or surgery. Left untreated it can lead to endotoxemia. In this example, the effect of feeding the probiotic strains of this invention on the translocation of the gut pathogen *Salmonella typhimurium* was examined.

Male Balb/c mice (6-8 weeks old) were daily fasted with 1×10^8 cfu in 0.2 ml of milk or milk alone for two weeks. After that, mice were either orally immunized or not with an inactivated *Salmonella* vaccine (10^8 cfu inactivated with paraphormaldehyde in 0.2 ml milk). After immunization, mice were fasted two weeks more with the probiotic preparations in alternate days for two weeks more. Two weeks after oral immunization, all mice were orally challenged with live *S. typhimurium* (10^{10} cfu in 0.2 ml milk).

Then, after 24-48 hours, the level of colonization of *S. typhimurium* in the spleen was determined in half of the animals. The rest of the animals were followed during two additional weeks in order to evaluate the survival of the animals after *Salmonella* infection.

5

The results obtained demonstrate that most of the probiotics tested potentiates the beneficial effect of the vaccination of mice with the inactivated *Salmonella* vaccine as shown in Figure 7.

10 **Example 6: Effect of *L. plantarum* CECT7262 or *L. reuteri* CECT7260 on the prevention of neonatal diarrhoea in neonatal piglets.**

15 The weaning of piglets at 3-4 weeks of age correlates with a high mortality rate in those animals mainly due to an increase in the incidence of diarrhoeal infections. Probably, this high mortality relates to a down-regulation of their defences due to the stressing modification of their nutritional and management status and to important changes in the composition of their gut microbiota.

20 For this reason, farmers have tried to solve this problem with the use of several approaches such as the use of antibiotics, immune-stimulant or mucosal protector components, such as colistine or ZnO. However, the EU ban of the use of antibiotics for animal production in 2006 has aggravated the situation. For this reason, the use of probiotics able to modulate the gut microbiota and the immune response appears as a potential alternative.

25

We compared the protective effect of the administration of 3×10^9 cfu/day of *L. reuteri* CECT7260 and *L. plantarum* CECT7262 versus the administration of an animal feed formulation containing 3000 ppm of ZnO and 40 ppm colistine in two groups of 48 and 45, respectively, weaned pigs for a period of 34 days.

30

In both groups, none of the animals suffered from diarrhoea nor died during the study, and the evolution of the body weight was also similar between both treatments,

suggesting that an animal feed formulation supplemented with these probiotics is, at least, as good as those containing conventional antibiotics and immune modulators.

Example 7: Effect of probiotic bacteria on inflammatory cytokines and IgG production

Besides the reduction of the risk of infection, many clinical effects associated to probiotic treatments are due to immunomodulatory capabilities of selected probiotic strains. The regulation of the immune response is usually mediated through a change in 10 the balance between pro-inflammatory cytokines (Th1) such as TNF- α , humoral cytokines (Th2) such as IL-4 or IL-13, and regulatory cytokines (Th3) such as IL-10 and TGF- β . Moreover, the bias in the immune response will also modulate the secretion 15 of immunoglobulins during the subsequent humoral response. For this reason, we have also tested the effect of some of the probiotic strains of this invention in regulating the expression of some of these clue cytokines and IgG.

We have used bone marrow-derived macrophages stimulated with 100 ng/ml of LPS (Sigma) as a cellular model. 10^5 macrophages/well were cultured in 24-well plastic plates (Nunc) with 1 ml of DMEM. Once attached, macrophages were stimulated or not 20 with 100 ng/ml LPS and with 10^7 cfu/ml of the indicated probiotic strains for 12 hours at 37°C in a 5% CO₂ atmosphere. Supernatants were collected and the production of cytokines was analyzed using a mouse TNF- α or mouse IL-10 ELISA (Biosource). The results obtained are summarized in Figure 8A and B.

25 The analysis of the effect of the probiotic strains of this invention on immunoglobulin production was performed using lymphocyte cultures obtained from the spleen of male Balb/c mice (6-8 weeks old). 2×10^6 lymphocytes were cultured in 1 ml DMEM in 24 well plastic plates and stimulated with inactivated probiotic cultures (10^8 cfu/ml) in presence or absence of 25 μ g/ml LPS for 6 days. The production of IgG by lymphocytes 30 was assessed using a mouse IgG ELISA from Bethyl (Figure 8C).

CLAIMS

- 1- A probiotic strain obtainable by the process of :
 - (i) isolating lactic acid bacteria or bifidobacteria strains present in the fresh milk from a mammalian species by selection in lactic acid culture media,
 - (ii) selecting those strains from step (i) that are capable of being transferred to the mammary gland after oral intake and/or colonise the mammary gland after its topical application,
 - (iii) selecting those strains from step (ii) which are able to reduce the rates of survival and/or the rates of adhesion to epithelial cells of *Staphylococcus aureus* and
 - (iv) selecting those strains from step (iii) that are capable of protecting animals from mastitis;
characterised in that the strain is selected from the group of *Bifidobacterium breve* deposited in the CECT under Accession N° 7263, *Bifidobacterium breve* deposited in the CECT under Accession N° 7264, *Lactobacillus reuteri* deposited in the CECT under Accession N° 7260, *Lactobacillus plantarum* deposited in the CECT under Accession N° 7262, *Lactobacillus fermentum* in the CECT under Accession N° 7265, *Lactobacillus reuteri* deposited in the CECT under Accession N° 7266, *Enterococcus hirae* EHG11 deposited in the CECT under Accession CECT 7410, *Lactobacillus plantarum* LG14 deposited in the CECT under Accession N° 7412, *Enterococcus faecalis* EFG1 deposited in the CECT under Accession No 7411, *Lactobacillus salivarius* CELA200 deposited in the CECT under Accession N° 7409, and *Lactobacillus reuteri* PDA3 deposited in the CECT under Accession N° 7413.
- 2- The probiotic strain according to claim 1 wherein the milk used in step (i) is selected from human, porcine, bovine, cat, ovine and canine milk.
- 3- A supernatant of a culture of a strain or of a mixture of strains as defined in claims 1 or 2.
- 4- A probiotic strain according to claims 1 or 2 or a mixture of strains according to claims 1 or 2 or a supernatant according to claim 3 for use as a medicament.

- 5- A composition, a pharmaceutical product, a feed or a nutritional product comprising at least a probiotic strain according to claims 1 or 2 or a supernatant as defined in claim 3.
- 6- A composition, pharmaceutical product, feed or nutritional product as defined in claim 5 which is in a frozen, lyophilized or dried form.
- 7- A composition, pharmaceutical product, feed or nutritional product as defined in claims 5 or 6 wherein the probiotic strain or the mixture thereof is in a partially or totally inactivated form.
- 8- Use of a probiotic strain according to claims 1 or 2 or a mixture thereof or a supernatant as defined in claim 3 for the manufacture of a medicament for the treatment and/or prophylaxis of a chronic or acute infection or infestation, or of an undesirable microbial colonization, wherein the infection, infestation or colonization is caused by parasites, bacteria, yeast, fungi or viruses, affecting any body surface or mucosa in a subject or animal in need thereof.
- 9- Use according to claim 8 wherein the infection is mastitis and the probiotic strain has been selected in step (i) using milk from the same species that is intended to be treated.
- 10- Use according to claim 8 wherein the infection is neonatal diarrhoea.
- 11- Use of a probiotic strain according to claims 1 or 2 or a mixture thereof or a supernatant as defined in claim 3 for the manufacture of a medicament for the treatment and/or prophylaxis of hypersensitivity reactions to food and metabolic intolerance; of constipation and other gastro-intestinal disorders; of inflammatory or auto-immune disorders selected from the group of IBD, ulcerative colitis, arthritis, atherosclerosis, multiple sclerosis, psoriasis or sarcoidosis; and of tumour growth, metastasis and cancer in subject or animal in need thereof.

- 12- Use of a probiotic strain according to claims 1 or 2 or a mixture thereof or a supernatant as defined in claim 3 for the manufacture of a medicament for the treatment and/or prophylaxis of allergic disorders and asthma in a subject or animal in need thereof.
- 13- Use of a probiotic strain according to claims 1 or 2 or a mixture thereof or a supernatant as defined in claim 3 for the manufacture of a medicament for treatment and/or prophylaxis of temporally depressed immune levels in individuals or animals subjected to physiological and management-derived stress.
- 14- Use according to claims 8 to 13 wherein the strain or composition is administered via oral, topic, nasal, enteral, ocular, urogenital, rectal or vaginal.
- 15- Use according to claims 8 to 13 wherein the strain, composition, pharmaceutical product, feed or nutritional product is designed to be administered to lactating woman or animal for the therapeutic or prophylactic treatment of the foetus and/or their breastfed babies or pups.

***Bifidobacterium breve* (CECT under Accession N° 7263)**

TCGNGTNNGAAGNACAATAAACACNTAAGTGCCTTGCTCCCTAACAAAAGA
 GGTTTACAACCCGCAAGGCCTCCATCCCTCACGCGGCGTCGCTGCATCAG
 GCTTGCGCCATTGATGCAATATTCCCCANTGCTGCCTCCGATANGAGT
 CTGGGCCGTATCTCAGTCCCAATGTGGCCGGTCGCCCTCTCAGGCCGGC
 TACCCGTGAAAGCCATGGTGGCCGTTACCCGCCATCAAGCTGATAGGA
 CGCGACCCCATCCCATGCCGAAAGGTTCCCAACACACCATGCGGTGT
 GATGGAGCATCCGGCATTACCAACCGTTCCAGGAGCTATTCCGGTGCAT
 GGGCAGGTCGGTCACGCATTACTCACCGTTGCCACTCTCACCACAG
 GCAAAGCCGATGGATCCCGTTGACTTGCATGTGTTAAGCACGCCGCCA
 GCGTTCATCCTGAGCCAGGATCAAACCTCTAA

***Bifidobacterium breve* (CECT under Accession N° 7264)**

TNCGCGANGAAGAAATAAAACAAAGTGCCTTGCTCCTAACAAAAGAGGTT
 TACAACCCGAANGCCTCCATNCCTCACGNNGNGTCNCATGCATCAGGCTT
 GCGCCCATGTGNAATATTCCCCACTGCTGCCTCCGTANGAGTCTGGGC
 CGTATCTNANTCCCAATGTGGCCGGTCGCCCTCTCAGGCCGGTACCCGT
 CGAAGCCATGGTGGCCGTTACCCGCCATCAAGCTGATAGGACGCGAC
 CCCATCCCATGCCGAAAGGTTCCCAACACACCATGCGGTGTGATGGA
 GCATCCGGCATTACCAACCGTTGCAGGAGCTATTCCGGTGCATGGGCA
 GGTGNGTNACGCATTACTNACCGTTGCCACTCTCACCACCAGGCAAAG
 CCCGATGGATCCCGTTGACTTGCATGTGTTAAGCACGCCGCCNGCGTTC
 ATCCNNAACAGGATCAAACCTCTAAA

***Lactobacillus reuteri* (CECT under Accession N° 7260)**

GCNTGGGNGAACGGTCACTGCGGAACAGTTACTCTCACGCACGTTCTCTCCAACAAACA
 GAGCTTACGAGCCAAACCTTCTTCACTCACGCGGTGTTGCTCCATCAGGCTTGC
 CCATTGTGGAAGATCCCTACTGCTGCCTCCCGTAGGAGTATGGACCGTGTCTCAGTTC
 CATTGTGGCGATCAGTCTCTCAACTCGGCTATGCATCATGCCCTGGTAAGCCGTTAC
 CTTACCAACTAGCTAATGCACCGCAGGTCCATCCAGAGTGATGCCAAAGCCATCTT
 CAAACAAAAGCCATGTGGCTTTGTTATGCGGTATTAGCATCTGTTCAAATGTT
 ATCCCCCGCTCCGGGGCAGGTTACCTACGTGTTACTCACCGTCCGCACTCACTGGTG
 ATCCATCGTCAATCAGGTGCAAGCACCATCAATCAGTTGGGCCAGTGCCTACGACTTGC
 ATGTATTAGGCACACCGCCGGCGTTACCTGAGNCAGGATCAAACCTCTAA

***Lactobacillus plantarum* (CECT under Accession N° 7262)**

GGCCTGGGAANCCGGTCATACTGGAACAGGTTACCTCTCAGATATGGTTCTTCTTAA
 CAACAGAGTTTACGAGCCAAACCTTCTTCACTCACGCGGCGTGCTCCATCAGACT
 TTCGTCCATTGTGGAAGATCCCTACTGCTGCCTCCCGTAGGAGTTGGGCCGTGTCTC
 AGTCCCAATGTGGCCGATTACCCCTCTCAGGTCGGCTACGTATCATTGCCATGGTGAGCC
 GTTACCTCACCATCTAGCTAATACGCCGGGACCATCCAAAAGTGATGCCAAGCCA
 TCTTCAAACCTCGGACCATGCGGTCCAAGTTGTTATGCGGTATTAGCATCTGTTCCAG
 GTGTTATCCCCGCTCTGGCAGGTTCCACGTGTTACTCACCAAGTTGCCACTCAC
 TCAAATGTAATTGATGCAAGCACCAATCATTACAGAGTTGCGTCACTGCATGTT
 ATTAGGCACGCCAGCGTTGAGACAGGATCAAACCTCTAA

2/11

Lactobacillus fermentum (CECT under Accession N° 7265)

TACACGATATGAACAGNTTACCTCTCATACGGTGNTTCTCTTTAACAAACAGAGCTT
 ACGAGCCGAAACCCCTCTCACTCACGCCGTGTCATCAGGCTTGCGCCCATG
 TGGAAGATTCCCTACTGCTGCCCTCCGTAGGAGTATGGGCCGTCTCAGTCCCATTG
 TGGCCGATCAGTCTCTCAACTCGGCTATGCATCATGCCCTGGTAGGCCGTACCCCA
 CCAACAAGCTAATGCACCGCAGGTCCATCCAGAAGTGATAGCGAGAACGCATCTTTA
 AGCGTTGTTCATGCGAACACAGNTGTTATGCGGTATTAGCATCTGTTCAAATGTTG
 TCCCCGCTTCTGGCAGGTTACCTACGTGTTACTCACCCGTCCGCCACTCGTTGGCG
 ACCAAAATCAATCAGGTGCAAGCACCATAATCAATTGGCCAACGCCGTTGACTTGC
 ATGTATTAGGCACACCGCCGGCGTTATCCTGAGCCAGGATCAAANTCTAA

Lactobacillus reuteri (CECT under Accession N° 7266)

ACCGNGGGNNAACGACACTGCGNGNACAGNTTACTCTCACGCACGNTTCTTCTCCAAC
 AACAGAGCTTACGAGCCGAAACCCCTCTCACTCACGCCGTGTCATCAGGCT
 TGCGCCCATTTGGAAGATTCCCTACTGCTGCCCTCCGTAGGAGTATGGACCCTGTCT
 CAGTCCATTGTGGCCGATCAGTCTCTCAACTCGGCTATGCATCATGCCCTGGTAAG
 CCGTTACCTTACCAACTAGCTAATGCACCGCAGGTCCATCCCAGAGTGATAGCCAAAG
 CCATCTTCAAACAAAGCCATGTGGCTTTGTTATGCGGTATTAGCATCTGTT
 CCAAATGTTATCCCCGCTCCGGGCAGGTTACCTACGTGTTACTCACCCGTCCGCCA
 CTCACTGGTGATCCATCGTCAATCAGGTGCAAGCACCATACTCAGTTGGCCAGTGC
 GTACGACTTGCATGTATTAGGCACACCGCCGGCGTTATCCTGAGCCAGGATCAAANT
 CTAA

Enterococcus hirae (CECT under Accession N° 7410)

GACAGTTACTCTCATCCTGTTCTCTAACAAACAGAGTTTACGATCCGAAAACCTT
 CTTCACTCACGCCGCGTTGCTCGGTAGACTTCTGTCATTGCCGAAGATTCCCTACTG
 CTGCCCTCCGTAGGAGTTGGCCGTGTCAGTCCCAATGTGGCCGATCACCTCTCA
 GGTGGCTATGCATCGCCTGGTGAGCCGTACCTCACCAACTAGCTAATGCACCG
 CGGGCCATCCATCAGCGACACCCGAAAGCGCCTTCAAATCAAACCATGCGGTTCG
 ATTGTTATACGGTATTAGCACCTGTTCCAAGTGTATCCCCTCTGATGGCAGGTTA
 CCCACGTGTTACTCACCGTTGCCACTCCTCTTTCCGGTGGAGCAAGCTCCGGTGG
 AAAAAGAAGCGTTGACTTGCATGTATTAGGCACGCCGCCAGCGTCTGAGCCAG
 GT

Lactobacillus plantarum (CECT under Accession N° 7412)

TTACTCTCAGATATGTTCTTAAACAAACAGAGTTTACGAGCCGAAACCCCTCTTCA
 CTCACGCCGCGTTGCTCCATCAGACTTCTGTCATTGTGGAAGATTCCCTACTGCTGCC
 TCCCGTAGGAGTTGGCCGTGTCAGTCCCAATGTGGCCGATTACCTCTCAGGTGCG
 GCTACGTATCATTGCCATGGTGAGCCGTACCCYACCATCTAGCTAATACGCCGCCGGA
 CCATCCAAAGTGTAGCCGAAGCCATCTTCAAGCTCGGACCATGCGGTCCAAGTTGT
 TATGCGGTATTAGCATCTGTTCCAGGTGTTATCCCCGCTCTGGCAGGTTCCCAC
 GTGTTACTCACCAGTTGCCACTCAAAATGAAATCATGATGCAAGCACCAATCAA
 TACCAGAGTTCGTTGACTTGCATGTATTAGGCACGCCGCCAGCGTCTGAGCCAG

Figure 1B

Enterococcus faecalis (CECT under Accession N° 7411)

CTATCATGCAAGTCGAACGCTCTTCTCCGAGTGCCTGCACCTCAATTGGAAAGAGG
 AGTGGCGGACGGGTGAGTAACACGTGGTAACCTACCCATCAGAGGGGATAACACTTG
 GAAACAGGTGCTAATACCGATAACAGTTATGCCGCATGGCATAAGAGTGAAAGGCGC
 TTTGGGTGTCGCTGATGGATGGACCCGGTGCATTAGCTAGTTGGTGAGGTAACGGC
 TCACCAAGGCCACGATGCATAGCCGACCTGAGAGGGTGATCGGCCACACTGGGACTGAG
 ACACGGCCCAGACTCCTACGGGAGGCAGCAGTAGGAACTTCGGCAATGGACGAAAGT
 CTGACCGAGCAACGCCGCGTGAAGAAGGTTTCGGATCGTAAACTCTGTTGTTA
 GAGAAGAACAGGACGTTAGTAACGTACCTGACGGTATCTAACAGAAAGCCA
 CGGCTAACTACGTGCCAGCA

Lactobacillus salivarius (CECT under Accession N° 7409)

GGGTGGGGNGANCAGAACATGAAATGAACAGTTACATCTCACCTCGCTGNTTCTCCT
 CTAACAACAGAGCTTACGACTCCGAAGGACCTCTCACATCACGCCGTNTGTC
 CATCAGACTTGCCTCATTGTGGAAGATTCCCTACTGCTGCCTCCGTAGGAGTTGGG
 CCGTGTCTCAGTCCCATGTGGCGATCAACCTCTCAGATTGGCTACGTATCATCACC
 TTGGTAGGCCGTACCCACCAACTAGTTAATACGCCGGGTCCATCTAAAAGCGATA
 GNAGAACCATTTCATCTAAGGATCATGCATCCTAGAGATATACGGNATTAGCACC
 TGTTTCCAAGTGTATCCCCTCTTTAGGCAGGTTACCCACGTGTTACTACCCGTCC
 GCCACTCAACTCTACGGTGAATGCAAGCATTGGTGAAGAAAGTTCGTTGACTT
 GCATGTATTAGGCACGCCAGCGTTGNTAGAGCCAGGATCAAACCTCTA

Lactobacillus reuteri (CECT under Accession N° 7413)

GCNTGGGNGAACGGTCACTGCGGAACAGTTACTCTCACGCACGTTCTTCTCCAACAACA
 GAGCTTACGAGCGAAACCCTCTCACTCACGCCGTGTTGCTCCATCAGGCTTGC
 CCATTGTGGAAGATTCCCTACTGCTGCCTCCGTAGGAGTATGGACCGTGTCTCAGTTC
 CATTGTGGCCGATCAGTCTCTCAACTCGGCTATGCATCATGCCCTGGTAAGCCGTAC
 CTTACCAACTAGCTAATGCACCCGAGGTCCATCCCAGAGTGATGCCAAAGCCATCTT
 CAAACAAAAGCCATGTGGCTTTGTTATGCGGTATTAGCATCTGTTCAAATGTT
 ATCCCCCGCTCCGGGGCAGGTTACCTACGTGTTACTCACCCGTCCGCACTCACTGGTG
 ATCCATCGTCAATCAGGTGCAAGCACCATACTAGTTGGGCCAGTGCCTACGACTTGC
 ATGTATTAGGCACACCGCCGGCGTTACCTGAGNCAGGATCNAACACTCTAA

Figure 1C




Figure 1D

5/11




Figure 2

6/11



A**B**

Figure 3

7/11




Figure 4




Figure 5

9/11




Figure 6

10/11






A**B**

Figure 7

11/11

A**B****C****Figure 8**

SEQUENCE LISTING

<110> PULEVA BIOTECH S.A.

<120> MAMMALIAN MILK MICROORGANISMS, COMPOSITIONS CONTAINING THEM AND
THEIR USE FOR THE TREATMENT OF MASTITIS

<130> P2922ES00

<160> 11

<170> PatentIn version 3.3

<210> 1

<211> 481

<212> DNA

<213> B.breve CECT 7263

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is a, c, g, or t

<220>

<221> misc_feature

<222> (7)..(8)

<223> n is a, c, g, or t

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is a, c, g, or t

<220>

<221> misc_feature

<222> (25)..(25)

<223> n is a, c, g, or t

<220>

<221> misc_feature
 <222> (131)..(131)
 <223> n is a, c, g, or t

<220>
 <221> misc_feature
 <222> (147)..(147)
 <223> n is a, c, g, or t

<400> 1
 tcgngtnnga agnacaataa acacntaagt gccttgctcc ctaacaaaag aggtttacaa 60
 cccgcaaggc ctccatccct cacgcggcgt cgctgcatca ggcttgcgcc cattgatgca 120
 atattcccca ntgctgcctc ccgatangag tctggccgt atctcagtcc caatgtggcc 180
 ggtcgccctc tcagggccggc taccgcgtca agccatggtg ggccgttacc ccgccccaa 240
 gctgatagga cgcgacccca tcccatgccc caaaggctt cccaacacac catgcggtgt 300
 gatggagcat ccggcattac cacccgttcc caggagctat tccggtgcat gggcaggtc 360
 ggtcacgcat tactcacccg ttgcgcactc tcaccaccag gcaaagcccg atggatcccg 420
 ttgcacttgc atgtgttaag cacgcccga gcgttcatcc tgagccagga tcaaactcta 480
 a 481

<210> 2
 <211> 476
 <212> DNA
 <213> B.breve CECT 7264

<220>
 <221> misc_feature
 <222> (2)..(2)
 <223> n is a, c, g, or t

```
<220>
<221> misc_feature
<222> (8)..(8)
<223> n is a, c, g, or t
```

```
<220>
<221> misc_feature
<222> (63)..(63)
<223> n is a, c, g, or t
```

```
<220>
<221> misc_feature
<222> (72)..(72)
<223> n is a, c, g, or t
```

```
<220>
<221> misc_feature
<222> (80)..(80)
<223> n is a, c, g, or t
```

```
<220>
<221> misc_feature
<222> (83)..(83)
<223> n is a, c, g, or t
```

```
<220>
<221> misc_feature
<222> (87)..(87)
<223> n is a, c, g, or t
```

```
<220>
<221> misc_feature
<222> (114)..(114)
<223> n is a, c, g, or t
```

```
<220>
<221> misc_feature
<222> (141)..(141)
<223> n is a, c, g, or t
```

```

<220>
<221> misc_feature
<222> (159)..(159)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (161)..(161)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (355)..(355)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (358)..(358)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (369)..(369)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (444)..(444)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (455)..(456)
<223> n is a, c, g, or t

<400> 2
tncgcganga agaaataaaa caaagtgcct tgctccctaa caaaagaggt ttacaacccg      60
aangcctcca tncctcacgn ggngtcncat gcatcaggct tgcgccatt gtgnaatatt      120

```

ccccactgct gcctcccgta ngagtctggg ccgttatctna ntcccaatgt ggccggtcgc 180
 cctctcaggc cggttacccg tcgaagccat ggtggccgt taccggcca tcaagctgat 240
 aggacgcgac cccatcccat gccgcaaagg ctgtccaaac acaccatgct gtgtgatgga 300
 gcatccggca ttaccacccg tttccaggag ctattccggt gcatggggca ggtcngtnac 360
 gcattactna cccgttcgccc actctcacca ccaggcaaag cccgatggat cccgttcgac 420
 ttgcatgtgt taagcacgccc gccngcgttc atccnnaaac aggtcaaac tctaaa 476

<210> 3
 <211> 515
 <212> DNA
 <213> *L. fermentum* CECT 7265

<220>
 <221> misc_feature
 <222> (17)..(17)
 <223> n is a, c, g, or t

<220>
 <221> misc_feature
 <222> (35)..(35)
 <223> n is a, c, g, or t

<220>
 <221> misc_feature
 <222> (313)..(313)
 <223> n is a, c, g, or t

<220>
 <221> misc_feature
 <222> (510)..(510)
 <223> n is a, c, g, or t

<400> 3

tacacgatat gaacagnnta cctctcatac ggtgnttctt ctttaacaac agagcttac	60
gagccgaaac ccttcttcac tcacgcggtg ttgctccatc aggcttgcgc ccattgtgga	120
agattcccta ctgctgcctc ccgttaggagt atgggccgtg tctcagtcac attgtggccg	180
atcaatgcacc gcaggtccat ccagaagtga tagcgagaag ccatcttta agcgttgttc	240
atgcgaacaa cgntgttatg cggtatttagc atctgttcc aaatgttgac ccccgcttct	300
ggcaggtta cctacgtgtt actcaccgt ccgccactcg ttggcgacca aaatcaatca	360
ggtgcaagca ccatcaatca attggccaa cgcgttcgac ttgcgttat taggcacacc	420
ccggcgttc atcctgagcc aggatcaa an tctaa	480
	515

<210> 4
 <211> 526
 <212> DNA
 <213> *L.reuteri* CECT 7266

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> n is a, c, g, or t

<220>
 <221> misc_feature
 <222> (9)..(10)
 <223> n is a, c, g, or t

<220>
 <221> misc_feature
 <222> (23)..(23)
 <223> n is a, c, g, or t

```

<220>
<221> misc_feature
<222> (25)..(25)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (30)..(30)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (46)..(46)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (521)..(521)
<223> n is a, c, g, or t

<400> 4
accgngggnn aacgacactg cgngnacagn ttactctcac gcacgnntct tctccaacaa 60
cagagcttta cgagccgaaa cccttcttca ctcacgcggt gttgctccat caggcttgcg 120
cccattgtgg  aagattccct actgctgcct cccgttaggag tatggaccgt gtctcagttc 180
cattgtggcc gatcagtctc tcaactcggc tatgcatcat cgccttggta agccgttacc 240
ttaccaacta gctaattgcac cgcaggtcca tcccagagtg atagccaaag ccattttca 300
aacaaaagcc atgtggctt tgggttatg cggtatttagc atctgtttcc aaatgttata 360
ccccgctccg gggcaggtta cctacgtgtt actcacccgt ccgccactca ctggtgatcc 420
atcgtcaatc aggtgcaagc accatcaatc agttgggcca gtgcgtacga cttgcgtatgt 480
ttaggcacac cgccggcggtt catcctgagc caggatcaa ntctaa 526

```

```

<210> 5
<211> 524
<212> DNA
<213> L.reuteri CECT 7260


<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (8)..(8)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (507)..(507)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (515)..(515)
<223> n is a, c, g, or t

<400> 5
gcntggng a cggtaactg cggAACAGTT acttcacgc acgttcttct ccaacaacag 60
agctttacga gccgaaaccc ttcttcaactc acgcgggttt gctccatcag gcttgcgccc 120
atgtggaag attccctact gctgcctccc gttaggatggatggatgtc tcagttccat 180
tgtggccgat cagtctctca actcggttat gcatcatcgc cttggtaagc cgttaccta 240
ccaaactagct aatgcacccgc aggtccatcc cagagtgata gccaaagcca tctttcaaac 300
aaaagccatg tggctttgt ttttatgcgg tattagcatc tttttccaaa ttatcccc 360
cgctccgggg caggttacct acgtgttact caccgtccg ccactcactg gtgatccatc 420

```

gtcaatcagg tgcaaggcacc atcaatcagt tgggccagtg cgtacgactt gcatgtatta 480

ggcacaccgc cggcgttcat cctgagncag gatcnaaact ctaa 524

<210> 6

<211> 519

<212> DNA

<213> L. plantarum CECT 7262

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is a, c, g, or t

<400> 6

ggcctggaa nccgtcata cctggaacag gttaccttc agatatggtt cttcttaac 60

aacagagttt tacgagccga aacccttctt cactcacgca gcgttgcctc atcagacttt 120

cgtccattgt ggaagattcc ctactgctgc ctcccgtagg agtttggcc gtgtctcagt 180

cccaatgtgg ccgattaccc tctcaggtcg gctacgtatc attgccatgg tgagccgtta 240

cctcaccatc tagctaatac gccgcggac catccaaaag tggatagccga agccatctt 300

caaactcggaa ccatgcggtc caagttgtta tgcggatttt gcatctgttt ccaggtgtta 360

tcccccgctt ctgggcaggt ttcccacgtg ttactcacca gttcgccact cactcaaatg 420

taattcatga tgcaaggcacc aatcattacc agagttcggtt cgacttgcat gtattaggca 480

cgccgcgcagc gttcgtcctg agacaggatc aaaactcta 519

<210> 7

<211> 474

<212> DNA

<213> Enterococcus hirae EHG11

<400> 7

gacagttact ctcatccttg ttcttcctca acaacagagt tttacgatcc gaaaaccttc	60
ttcactcacg cggcggttgct cggtcagact ttcgtccatt gccgaagatt ccctactgct	120
gcctcccgta ggagtttggg ccgtgtctca gtcccaatgt ggccgatcac cctctcaggt	180
cggctatgca tcgtcgccctt ggtgagccgt tacctcacca actagctaatt gcaccgcggg	240
tccatccatc agcgacaccc gaaagcgccct ttcaaatcaa aaccatgcgg tttcgattgt	300
tatacggtat tagcacctgt ttccaagtgt tatccccttc tcatggcag gttacccacg	360
tgttactcac ccgttcgcca ctcctcttt tccgggtggag caagctccgg tggaaaaaga	420
agcgttcgac ttgcatgtat taggcacgccc gccagcggttc gtcctgagcc aggt	474

<210> 8

<211> 469

<212> DNA

<213> Lactobacillus plantarum LG14:

<400> 8

ttactctcag atatgttctt cttaacaac agagtttac gagccaaac ccttcttcac	60
tcacgcggcg ttgctccatc agactttcgt ccattgtgga agattcccta ctgctgcctc	120
ccgtaggagt ttggggccgtg tctcagtcgg aatgtggccg attaccctct caggtcggct	180
acgtatcatt gccatggtga gcccgttaccc caccatctag ctaatacgcc gcgggaccat	240
ccaaaagtga tagccgaagc catcttcaa gctcggacca tgcggtccaa gttgttatgc	300
ggtattagca tctgtttcca ggtgttatcc cccgcttctg ggcaggtttc ccacgtgtta	360
ctcaccagtt cgccactcac tcaaattgtaa atcatgatgc aagcaccaat caataccaga	420

gttcgttcga ctgcgtatgtat ttaggcacgc cgccagcggtt cgtcctgag 469

<210> 9

<211> 493

<212> DNA

<213> Enterococcus faecalis EFG1:

<400> 9

ctatcatgca agtcgaacgc ttctttcctc ccgagtgctt gcactcaatt ggaaagagga 60

gtggcggacg ggtgagtaac acgtggtaa cctaccatc agagggggat aacacttgg 120

aacagggtct aataccgcat aacagtttat gccgcatggc ataagagtga aaggcgcttt 180

cgggtgtcgc tcatggatgg acccgcggtg cattagctag ttggtgaggt aacggctcac 240

caaggccacg atgcatagcc gacctgagag ggtgatcgcc cacactggga ctgagacacg 300

gccccagactc ctacgggagg cagcagtagg gaatcttcgg caatggacga aagtctgacc 360

gagcaacgcc gcgtgagtga agaaggttt cggatcgtaa aactctgttg ttagagaaga 420

acaaggacgt tagtaactga acgtccctg acggtatcta accagaaagc cacggctaac 480

tacgtgcccc gca 493

<210> 10

<211> 524

<212> DNA

<213> Lactobacillus salivarius CELA200:

<220>

<221> misc_feature

<222> (9)..(9)

<223> n is a, c, g, or t

<220>

```

<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (51)..(51)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (113)..(113)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (297)..(297)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (345)..(345)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (503)..(503)
<223> n is a, c, g, or t

<400> 10
gggtgggng ancagaacat gaaatgaaca gtttacatct cacctcgctg nttttcctc 60

taacaacaga gctttacga ctccgaagga ctttcttacatc atcacgcggc gtntgctcca 120

tcagacttgc gtccattgtg gaagattccc tactgctgcc tcccgtagga gtttggggccg 180

tgtctcagtc ccaatgtggc cgatcaacct ctcagattcg gctacgtatc atcaccttgg 240

taggccgtta ccccaccaac tagttaatac gccgcgggtc catctaaaag cgatagnaga 300

```

accatcttc atctaaggat catgcgatcc ttagagatat acggnattag cacctgtttc 360
 caagtgttat ccccttcttt taggcaggtt acccacgtgt tactcacccg tccgccactc 420
 aacttcttac ggtgaatgca agcattcggt gtaagaaagt ttcgttcgac ttgcatgtat 480
 taggcacgccc gccagcggtc gtnatgagcc aggatcaaac tcta 524

<210> 11
 <211> 524
 <212> DNA
 <213> *Lactobacillus reuteri* PDA3:

<220>
 <221> misc_feature
 <222> (3)..(3)
 <223> n is a, c, g, or t

<220>
 <221> misc_feature
 <222> (8)..(8)
 <223> n is a, c, g, or t

<220>
 <221> misc_feature
 <222> (507)..(507)
 <223> n is a, c, g, or t

<220>
 <221> misc_feature
 <222> (515)..(515)
 <223> n is a, c, g, or t

<400> 11
 gcntggngaa acggtaactg cggaacagtt actctcacgc acgttcttct ccaacaacag 60
 agctttacga gccgaaaccc ttcttcactc acgcgggttt gctccatcag gcttgcgccc 120

attgtggaag attccctact gctgcctccc gtaggagtat ggaccgtgtc tcagttccat 180
tgtggccgat cagtctctca actcggtat gcatcatcgc cttggtaagc cgttaccta 240
ccaactagct aatgcaccgc aggtccatcc cagagtgata gccaaagcca tctttcaaac 300
aaaagccatg tggctttgt tttatgcgg tattagcatc tttttccaaa ttttatcccc 360
cgctccgggg caggttacct acgtgttact caccgtccg ccactcactg gtgtatccatc 420
gtcaatcagg tgcaagcacc atcaatcagt tggccagtg cgtacgactt gcatgttatta 480
ggcacaccgc cggcggtcat cctgagncag gatcnaaact ctaa 524